

## ASX Announcement

### Regeneus Announces Successful Results in Acne Study

Sydney, Australia – 6 February 2018

- Sygenus topical gel improves the appearance of acne in adults
- Sygenus gel was well tolerated when applied twice daily for 6 weeks
- Significant reduction seen in the appearance of non-inflammatory lesions such as blackheads and whiteheads, and inflammatory papules
- Significant reduction noted in acne global severity score at 6 weeks

Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.

Sygenus is a patented allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells (MSCs). These bioactive molecules work to reduce pain and inflammation and encourage accelerated healing and repair.

#### Study results

The tolerance study, performed by RCTS, a dermatology testing company in Texas, aimed to look at the tolerability of Sygenus in 33 healthy volunteers with mild to moderate facial acne. The study endpoints to assess tolerability involved the change in acne lesions over the 6-week period. Sygenus gel was applied topically twice a day throughout the study. No intolerance was observed and there was an overall improvement in the appearance of acne, as early as 3 weeks. Statistically significant reductions in the total number of inflammatory and non-inflammatory acne lesions were noted from baseline to week 6. Further the acne global severity score showed significant reduction (improvement) at week 6 compared to baseline.

These promising results will help in the partnering of Sygenus gel for the acne market and other inflammatory skin conditions. With few treatment innovations or improvements without significant side effects in the treatment of acne over the last 10 years, the demand for new improved acne treatments is high.

Regeneus has received granted patents in Australia, Europe, China, USA and Japan covering the composition, manufacture and use of the Sygenus technology for the topical treatment of acne. The company also has patent applications for the use of Sygenus for a broad range of other inflammatory skin conditions.

#### More about Sygenus

Sygenus is a patented allogeneic cell secretions technology platform that utilises the molecules (including cytokines, growth factors and exosomes) that are secreted by donor adipose-derived MSCs and work to reduce pain and inflammation and encourage accelerated healing and repair. Regeneus has developed technology and intellectual property for the scalable production of secretions of MSCs which have the potential to be used as an off-the-shelf treatment for multiple indications and in a range of delivery methods.

A key area of research focus is the use of Sygenus technology for the treatment of pain. The company reported on 26 September 2017 that a preclinical post-operative pain study has shown that topical application of Sygenus has significantly and longer lasting analgesic effect than an injection of morphine. The company is investigating the use of its stem cell technologies for the treatment of pain in an ARC Linkage program with the University of Adelaide and Macquarie University.

ENDS

#### **About Regeneus**

Regeneus Ltd (ASX: RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

#### **Contact for further information**

##### **Investors**

Sandra McIntosh  
Company Secretary and Investor Relations  
Regeneus Ltd  
T: +61 2 9499 8010  
E: [investors@regeneus.com.au](mailto:investors@regeneus.com.au) or go to <http://www.regeneus.com.au>